April 12, 2012 - Abiomed Inc., a provider of heart support technologies, announced it has received CE marking approval in the European
Union to market the Impella cVAD device, a new percutaneous Impella heart pump that provides peak flow of approximately 4 liters of blood per minute. The Impella cVAD is designed to provide temporary circulatory support via a minimally invasive, catheter-based pump that is insertedpercutaneously, without the need for surgical intervention.